Your browser doesn't support javascript.
loading
Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma.
Oshima, Sonoko; Hagiwara, Akifumi; Raymond, Catalina; Wang, Chencai; Cho, Nicholas S; Lu, Jianwen; Eldred, Blaine S C; Nghiemphu, Phioanh L; Lai, Albert; Telesca, Donatello; Salamon, Noriko; Cloughesy, Timothy F; Ellingson, Benjamin M.
Afiliación
  • Oshima S; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, California, USA.
  • Hagiwara A; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • Raymond C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, California, USA.
  • Wang C; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • Cho NS; Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan.
  • Lu J; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, California, USA.
  • Eldred BSC; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • Nghiemphu PL; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, California, USA.
  • Lai A; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • Telesca D; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, California, USA.
  • Salamon N; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • Cloughesy TF; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, California, USA.
  • Ellingson BM; Medical Scientist Training Program, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Neurooncol Adv ; 5(1): vdad084, 2023.
Article en En | MEDLINE | ID: mdl-37554221
ABSTRACT

Background:

Alterations in tumor growth rate (TGR) in recurrent glioblastoma (rGBM) after treatment may be useful for identifying therapeutic activity. The aim of this study was to assess the impact of volumetric TGR alterations on overall survival (OS) in rGBM treated with chemotherapy with or without radiation therapy (RT).

Methods:

Sixty-one rGBM patients treated with chemotherapy with or without concomitant radiation therapy (RT) at 1st or 2nd recurrence were retrospectively examined. Pre- and post-treatment contrast enhancing volumes were computed. Patients were considered "responders" if they reached progression-free survival at 6 months (PFS6) and showed a decrease in TGR after treatment and "non-responders" if they didn't reach PFS6 or if TGR increased.

Results:

Stratification by PFS6 and based on TGR resulted in significant differences in OS both for all patients and for patients without RT (P < 0.05). A decrease of TGR (P = 0.009), smaller baseline tumor volume (P = 0.02), O6-methylguanine-DNA methyltransferase promoter methylation (P = 0.048) and fewer number of recurrences (P = 0.048) were significantly associated with longer OS after controlling for age, sex and concomitant RT.

Conclusion:

A decrease in TGR in patients with PFS6, along with smaller baseline tumor volume, were associated with a significantly longer OS in rGBM treated with chemotherapy with or without radiation. Importantly, all patients that exhibited PFS6 also showed a measurable decrease in TGR.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Neurooncol Adv Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Neurooncol Adv Año: 2023 Tipo del documento: Article